Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant

References

• Vardiman JW, Thiele J, Arber DA, et al The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Smith SM, Le Beau MM, Huo D, et al Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43–52.
   PubMed Web of Science ®Google Scholar
• Olney HJ, Mitelman F, Johansson B, Mrozek K, Berger R, Rowley JD. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:413–423.
   PubMed Web of Science ®Google Scholar
• Offman J, Opelz G, Doehler B, et al Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822–828.
   PubMed Web of Science ®Google Scholar
• Takeyama K, Seto M, Uike N, et al Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000;71:144–152.
   PubMed Web of Science ®Google Scholar
• Godley LA, Larson RA. The syndrome of therapy-related myelodysplasia and myeloid leukemia. In: Bennett JM, editor. The myelodysplastic syndromes: pathobiology and clinical management. New York: Marcel Dekker; 2002. pp 139–176.
   Google Scholar
• Anderson JE, Gooley TA, Schoch G, et al Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997;89:2578–2585.
   PubMed Web of Science ®Google Scholar
• Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000;18:963–971.
   PubMed Web of Science ®Google Scholar
• Hale GA, Heslop HE, Bowman LC, et al Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999;24:735–739.
   PubMed Web of Science ®Google Scholar
• Kroger N, Brand R, van Biezen A, et al Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 2006;37:183–189.
   PubMed Web of Science ®Google Scholar
• Devemy E, Li B, Tao M, et al Poor prognosis acute myelogenous leukemia: 3–biological and molecular biological changes during remission induction therapy. Leuk Res 2001;25:783–791.
   PubMed Web of Science ®Google Scholar
• Linker CA, Owzar K, Powell B, et al Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant 2009;44:353–359.
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S, et al Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728–5738.
   PubMed Web of Science ®Google Scholar
• Rich ES, Artz A, Karrison T, et al Allogeneic hematopoietic cell transplantation from combined haploidentical family members and unrelated cord blood (CB) can benefit high risk patients lacking HLA-identical donors. Blood 2009;114(Suppl. 1): (Abstract 3378).
   Google Scholar
• van Besien K, Kline J, Godley LA, et al Phase I-II study of clofarabine-melphalan-alemtuzumab (CMA) conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies: determination of MTD and outcomes. Blood 2009;114(Suppl. 1): (Abstract 197).
   Google Scholar
• O'Donnell PH, Artz AS, Undevia SD, et al Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplantation. Submitted.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox D. Regression models and life-tables. J R Stat Soc B 1972;34:187–220.
   Google Scholar
• Haferlach T, Kern W, Schoch C, et al A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group. Haematologica 2004;89:408–418.
   PubMed Web of Science ®Google Scholar
• Preisler HD, Venugopal P, Gregory SA, et al Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine). Leuk Res 2000;24:671–680.
   PubMed Web of Science ®Google Scholar
• Seiter K, Liu D, Feldman E, et al Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma 2006;47:425–432.
   PubMed Web of Science ®Google Scholar
• Buchner T, Berdel WE, Schoch C, et al Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006;24:2480–2489.
   PubMed Web of Science ®Google Scholar
• Braess J, Spiekermann K, Staib P, et al Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009;113:3903–3910.
   PubMed Web of Science ®Google Scholar
• Buchner T, Berdel WE, Haferlach C, et al Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61–69.
   PubMed Web of Science ®Google Scholar
• Allen SL, Kolitz JE, Lundberg AS, Bennett JM, Capizzi RL, Budman DR. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leuk Res 2010;34:487–491.
   PubMed Web of Science ®Google Scholar
• Kolitz JE, George SL, Dodge RK, et al Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 2004;22:4290–4301.
   PubMed Web of Science ®Google Scholar
• Weiss M, Maslak P, Feldman E, et al Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996;14:2480–2485.
   PubMed Web of Science ®Google Scholar
• Damon LE, Wolf JL, Rugo HS, et al High-dose chemotherapy (CTM) for breast cancer. Bone Marrow Transplant 2000;26:257–268.
   PubMed Web of Science ®Google Scholar
• Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:395–400.
   PubMed Web of Science ®Google Scholar